Dictionary

allow_url_fopen is ENABLED Dictionary Search

factor ix

Synonyms

Noun

1. Christmas factor

2. factor IX, coagulation factor, clotting factor

Usage
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Advances in hemophilia, sickle cell disease, and thalassemia - Penn Medicine
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Explainer 2025 Why Is Hemophilia B Called Christmas Disease - Global Biotechnology Company
AAV gene therapy shows durable benefit in hemophilia B - 2 Minute Medicine
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Systemic lupus erythematosus caused acquired hemophilia B without evidence of factor IX inhibitors - Wiley Online Library
Hemophilia B Gene Therapy Continues to Reduce Bleeding - Medscape
Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting - Biogen
Clinical trial: Hemophilia B, (NCT06379789) - CRISPR Medicine - CRISPR Medicine News
Critical shortage of blood products in Afghanistan - The Lancet
Exploring gene editing as a potential therapeutic strategy for hemophilia - Frontiers
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years - MedPage Today
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report - Wiley
How Gene Therapy Is Transforming Hemophilia B Treatment - Docwire News
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B | New England Journal of Medicine - The New England Journal of Medicine
How durable is gene therapy for haemophilia B? - Nature
HOPE-B Shows Bleeding Control Still Holding at 5 Years - Docwire News
Clinical Trial’s 13 Years of Follow-Up: Gene Therapy Is Effective, Safe for Hemophilia B - Docwire News
EVOLVING THE TREATMENT LANDSCAPE WITH THE FIRST THERAPY APPROVED FOR PEOPLE WITH HEMOPHILIA A AND B WITH OR WITHOUT INHIBITORS - AJMC
One dose of gene therapy gives years of relief from blood disorder - Nature
Hemophilia B: Gene Therapy Shows 5-Year Success - Medscape
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial - Applied Clinical Trials
Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later - MedPage Today
Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade - Managed Healthcare Executive
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
Use of anti-haemophilia medicine suspended across Punjab after reports of adverse reactions - Tribune India
Multiyear Follow-up Study Shows Positive Results for Hemophilia B Gene Therapy - Managed Healthcare Executive
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - The New England Journal of Medicine
NICE Recommends First Subcutaneous Option for Haemophilia B - Medscape
Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product - Nature
Haemophilia gene therapy patients thriving over a decade after treatment - University College London
Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with hemophilia A or B - News-Medical
This gene therapy costs $5 million a dose. Is it worth the price? - SMH.com.au
UK Approves Marstacimab for Severe Haemophilia A or B - Medscape
X-Factor (2024) #9 - Marvel.com
Six biotech companies leading the charge in hemophilia treatment - Labiotech.eu
Wolfgang Miesbach: Monitoring Patients after Etranacogene Dezaparvovec Gene Therapy - Oncodaily
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
Hemophilia B: Post-Beqvez, What’s Next for Gene Therapy? - Medscape
Hemlibra: Dosage, cost, side effects, and more - Medical News Today
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
Marvel Preview: X-Factor #9 - AIPT
Hemgenix Gene Therapy Shows Sustained Benefits Over 5 Years in Hemophilia B: NEJM - Medical Dialogues
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - The New England Journal of Medicine
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies - Nature
Coagulation Factors Market Size, Share, Analysis | Report [2034] - Fortune Business Insights
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B - BioSpace
Recombinant factor IX Fc for the treatment of hemophilia B - Ljung - 2024 - European Journal of Haematology - Wiley Online Library
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years - Mynewsdesk
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) | New England Journal of Medicine - The New England Journal of Medicine
Plasma factor IX: The tip of the iceberg? - Sidonio - 2021 - Haemophilia - Wiley Online Library
X-Factor #9 Preview: Havok's Past Haunts the Team - Bleeding Cool News
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX - Nature
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence - Nature
Pfizer’s Hympavzi granted MHRA approval to treat haemophilia A and B - PMLiVE
New Recombinant Factor IX Leads to Significant Cost Savings in Hemophilia B - AJMC
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space - Wiley
Ixinity (trenonacog alfa) for hemophilia - Hemophilia News Today
Association Between Hepatic Triglyceride Content and Coagulation Factors: - American Heart Association Journals
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab - American Heart Association Journals
Ultrasound-targeted hepatic delivery of factor IX in hemophiliac mice - Nature
HTC Population Profile Patient Characteristics - Centers for Disease Control and Prevention | CDC (.gov)
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
First gene therapy to treat haemophilia B - European Medicines Agency
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector - Nature
Intellia opts out of hemophilia B gene editing work with Regeneron - Fierce Biotech
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis - American Heart Association Journals
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors - Nature
Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen - Wiley Online Library
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X - PNAS
Gene therapy fails to induce sustained factor IX activity for patients with hemophilia B - Healio
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B - 2 Minute Medicine
Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients - 2 Minute Medicine
Hemophilia therapy: the future has begun - Haematologica
Glucocorticoids increase adiposity by stimulating Krüppel-like factor 9 expression in macrophages - Nature
Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria - Nature
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma - Nature
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis - MedPage Today
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study - The Lancet
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A - The New England Journal of Medicine
Get easily bruised? It may be due to haemophilia B - healthshots.com
Fibroblast Growth Factor 9 as a Potential Biomarker for Schizophrenia - Frontiers
Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A - Frontiers
Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice - Nature
Researchers welcome $3.5-million haemophilia gene therapy — but questions remain - Nature
Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B - 2 Minute Medicine
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity - Wiley Online Library
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response - Nature
Hemophilia B Gene Therapy Achieves Sustained Benefit Over 4 Years - HCPLive
Haemophilia B Due to a De Novo Insertion of a Human-Specific Alu Subfamily Member within the Coding Region of the Factor IX Gene - Nature
Haemophilia - The Lancet
Foreign Language Equivalents
Foreign Language Equivalents of 'factor ix'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
factor x,   factor ox,   factot ix,   facyor ix,   factor ixx,   factoor ix,   facto ix,   factir ix,   facctor ix,   afctor ix,   factpr ix,   facror ix,   ffactor ix,   factr ix,   fcator ix,   factorix,   factor ix,   factor xi,   factoe ix,   dactor ix,   factor ic,   factori x,   factro ix,   fctor ix,   fatcor ix,   faxtor ix,   factorr ix,   facttor ix,   facto rix,   fator ix,   facter ix,   faactor ix,   facotr ix,   fsctor ix,   gactor ix,   factor i,   facor ix,   factor iz,   factor iix,   actor ix,   favtor ix,   factor ux
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z